Psoriasis symptoms study, new blog top dermatology reads of week

Study results reporting psoriasis and acne symptoms respond to seasonal variations was the most-read article of the past week on Healio.com/Dermatology.

Other widely read articles included Glenmark Phamaceuticals S.A.’s initiation of a phase 2 study of a novel monoclonal antibody in atopic dermatitis and the debut of a new blog focusing on cosmetic dermatology:

Psoriasis, acne respond to seasonal variations

Symptoms of psoriasis and acne significantly cleared during the summer and worsened in the winter, according to recently published study results.

Researchers used physician’s global assessment (PGA) scores to determine seasonal variation in psoriasis and acne. Data were collected between June 2011 and May 2014 in New England. Read more

Glenmark to begin phase 2 studies in atopic dermatitis, celiac disease

Glenmark Pharmaceuticals S.A. announced it has begun preparations to initiate phase 2 studies of GBR 830, a novel monoclonal antibody, in atopic dermatitis and celiac disease, according to a press release.

The phase 2 studies in the United States and Europe are supported by safety and pharmacokinetics results of phase 1 studies in the Netherlands of GBR 830, an antagonist of OX40, a constimulatory receptor expressed on T cells, according to the release. Read more

Psoriasis, herpes labialis highly stigmatizing, image-based survey reports

Participants of an image-based survey found images of psoriasis to be as bothersome as those of herpes labialis in some categories, according to recently published study results.

Researchers used an image-based questionnaire to study and compare the public’s attitude towardpsoriasis, to identify factors that contribute to its stigmatization and to compare perceptions of psoriasis against other common dermatological conditions including atopic dermatitis, acne, vitiligo, rosacea, herpes labialis, warts and tinea versicolor. Read more

FDA grants orphan drug status to Humira for treatment of hidradenitis suppurativa

AbbVie announced that the FDA has granted orphan drug designation to Humira for treating moderate-to-severe hidradenitis suppurativa.

The supplemental biologic license application by Abbvie seeking the agency’s approval for the use of Humira (adalimumab) in patients with moderate-to-severe hidradenitis suppurativa (Hurley Stage II and Hurley Stage III disease) is being reviewed by the FDA, according to a press release. Read more

BLOG: Global advances in minimally invasive aesthetics

Kimberly J. Butterwick, MD, a dermatologist in private practice in San Diego, Calif., and new blogger focusing on cosmetic dermatology for Healio.com/Dermatology, discussed “The State of the Art in Minimally Invasive Aesthetics” session sponsored by the American Society of Dermatologic Surgery, held before the start of the World Congress of Dermatology.

Kimberly J. Butterwick

“Given that the FDA had just issued a warning about vascular adverse events related to fillers, the sessions on fillers were particularly timely and informative,” Butterwick wrote. Read more